Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
GLOBETECH MEDIA

Experimental Drug Prevents Ischemia in Mouse Muscular Dystrophy Model

By BiotechDaily International staff writers
Posted on 22 Nov 2012
Treating mice with a form of muscular dystrophy that closely mimics human Duchenne muscular dystrophy (DMD) with the experimental drug HCT 1026 restored normal blood flow to muscles stressed by a hormone-induced exercise regimen.

The dystrophin deficiency that characterizes DMD causes loss of the neuronal enzyme nitric oxide synthase from the sarcolemma, producing functional ischemia when the muscles are exercised. Investigators at Cedars-Sinai Heart Institute (Los Angeles, CA, USA) asked whether functional muscle ischemia could be eliminated and normal blood flow regulation restored by treatment with an exogenous nitric oxide (NO)-donating drug.

The drug under evaluation was HCT 1026, a NO-donating nonsteroidal anti-inflammatory agent that had previously been shown to slow progression of DMD in the mdx mouse muscular dystrophy model.

In the current study, beginning at eight weeks of age, mdx mice were fed a standard diet supplemented with 1% soybean oil alone or in combination with a low or high dose of HCT 1026. After one month of treatment, vasoconstrictor responses to intra-arterial norepinephrine (NE) were compared in resting and contracting hindlimbs.

Results published in the November 5, 2012, online edition of the journal PLOS ONE revealed that in untreated mdx mice, the usual effect of muscle contraction to attenuate NE-mediated vasoconstriction was impaired, resulting in functional ischemia. This NE-induced functional ischemia was unaffected by low dose HCT 1026 but was alleviated by the high dose of the drug. The beneficial effect of high dose HCT 1026 was maintained with treatment up to three months.

"There is an urgent unmet need for effective therapeutic options for this devastating disease," said senior author Dr. Ronald G. Victor, professor of cardiology at Cedars-Sinai Heart Institute. "If we can improve blood flow in muscular dystrophy patients, we may be able to preserve some muscle function over a longer period of time."

The authors stressed that they did not expect these novel nitric oxide-donating compounds to cure DMD, but did hope that the improved blood flow that they induced could reduce muscle fatigue and injury, allowing patients to be more active while slowing down the loss of vital muscle tissue.

Related Links:
Cedars-Sinai Heart Institute




Channels

Drug Discovery

view channel
Image: Star-like glial cells in red surround alpha-beta plaques in the cortex of a mouse with a model of Alzheimer\'s disease (Photo courtesy of Strittmatter laboratory/Yale University).

Experimental Cancer Drug Reverses Symptoms in Mouse Model of Alzheimer's Disease

An experimental, but clinically disappointing drug for treatment of cancer has been found to be extremely effective in reversing the symptoms of Alzheimer's disease (AD) in a mouse model.... Read more

Biochemistry

view channel
Image:  Model depiction of a novel cellular mechanism by which regulation of cryptochromes Cry1 and Cry2 enables coordination of a protective transcriptional response to DNA damage caused by genotoxic stress (Photo courtesy of the journal eLife, March 2015, Papp SJ, Huber AL, et al.).

Two Proteins Critical for Circadian Cycles Protect Cells from Mutations

Scientists have discovered that two proteins critical for maintaining healthy day-night cycles also have an unexpected role in DNA repair and protecting cells against genetic mutations that could lead... Read more

Business

view channel

NanoString and MD Anderson Collaborate on Development of Novel Multi-Omic Expression Profiling Assays for Cancer

The University of Texas MD Anderson Cancer Center (Houston, TX, USA) and NanoString Technologies, Inc. (Seattle, WA, USA) will partner on development of a revolutionary new type of assay—simultaneously profiling gene and protein expression, initially aiming to discover and validate biomarker signatures for immuno-oncology... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.